2015-11-12 08:18 ET - News Release
Dr. Elliot Goldstein reports
PROMIS NEUROSCIENCES ANNOUNCES ACQUISITION OF EXCLUSIVE WORLDWIDE LICENSE TO NOVEL THERAPEUTIC TARGET FOR ALZHEIMER'S DISEASE
to its expanded licence agreement with the University of British
Columbia, as announced on Oct. 8, 2015, ProMIS Neurosciences Inc. has
acquired an exclusive, worldwide licence to a novel Alzheimer's disease
target. A provisional patent application for this target was submitted
to the United States Patent Office on Monday, Nov. 9, 2015. The amino
acid sequence of this novel target has not been disclosed.
Company applied its unique, proprietary discovery platform, in
particular the recently acquired Collective Coordinates method (see
announcement of Nov. 11, 2015), to identify and confirm the presence of
this novel target (epitope) on strains of misfolded beta Amyloid.
Misfolded, propagating strains of beta Amyloid are known to be
neurotoxic and widely believed by the scientific community to play a key
role in the development and progression of Alzheimer's disease.
acquisition of this first target on misfolded beta Amyloid is an
important milestone in the Company's mission to discover and develop
precision medicine solutions for the early detection and effective
treatment of Alzheimer's disease. ProMIS will continue to use its
proprietary platform to discover further targets for precision medicine
solutions via identification of novel target epitopes on other misfolded
strains of beta Amyloid, as well as on misfolded strains of Tau,
another protein implicated in neurodegenerative diseases, including
Commenting on the acquisition of the new Alzheimer's
target, ProMIS CEO, DR Elliot Goldstein stated: " We are delighted with
the pace of innovation and discovery accomplished by our science team,
using ProMIS' proprietary techniques. The discovery of this novel target
for Alzheimer's is the critical step in creating the first in a series
of precision medicine solutions for this devastating disease. With this
target to hand, we are well positioned for development of a precision
therapeutic and companion diagnostic for patients whose disease may be
driven by this toxic strain of beta Amyloid ".
announced, a live webcast to review third quarter results, present the
Company's near term plans and address questions from the audience will
be held at 11:00AM, Eastern Standard Time.
To join the webcast, please
go to the link below:
those unable to attend, the recorded version will be available after
the webcast on the Company website: www.promisneurosciences.com